Immunotherapy nearly doubles survival time in early-stage lung cancer trial

Adding the immunotherapy drug atezolizumab to chemotherapy before and after surgery nearly doubled the time patients with early-stage lung cancer lived without their disease returning, according to final results from the Phase 3 IMpower030 trial presented on September 12 at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.bioengineer+1

Patients with resectable stage IIB to IIIB non-small cell lung cancer who received perioperative atezolizumab plus platinum-based chemotherapy achieved a median event-free survival of 62.8 months, compared with 34.9 months for those treated with chemotherapy and placebo — a difference of nearly two and a half years. The trial, sponsored by Roche ↗ 1.42% and Genentech, enrolled patients without EGFR or ALK alterations.onclive+1

Pathological Responses and Efficacy

Beyond the survival data, the atezolizumab regimen produced markedly higher rates of tumor destruction before surgery. Pathological complete response — meaning no viable cancer cells remained in the removed tumor — was achieved in 29.6 percent of patients in the atezolizumab arm versus 8.5 percent with chemotherapy alone. Major pathological response, defined as 10 percent or less residual viable tumor, reached 53.6 percent compared with 24.4 percent.news-medical+1

Despite these improvements, the trial did not meet its prespecified threshold for statistical significance on its primary endpoint. Investigators nonetheless reported clinically meaningful gains across multiple measures, including event-free survival assessed by both an independent review facility and treating investigators, disease-free survival, and overall survival.bioengineer+1

Safety and Surgical Feasibility

The perioperative approach did not compromise patients' ability to undergo surgery. Surgical cancellation rates remained low and similar between the two groups, and no new safety signals emerged. Adverse events were more common during the neoadjuvant phase than the adjuvant phase in both arms, consistent with the combined intensity of chemotherapy and immunotherapy delivered before surgery.news-medical+1

Implications for Lung Cancer Treatment

"These long-term findings demonstrate clinically meaningful improvements across several important outcomes and further support the role of perioperative immunotherapy for patients with resectable NSCLC," said Benjamin Solomon, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, who presented the findings.news-medical

Non-small cell lung cancer remains the leading cause of cancer death worldwide, and relapse rates after surgery have historically been high even when the disease is caught at an operable stage. The five-year median event-free survival reported in IMpower030 suggests a meaningful proportion of patients may be experiencing durable disease control, though the failure to meet formal statistical significance leaves open questions about how the data will be weighed by regulators and treatment guideline committees.bioengineer